Patients are asking about the “Wolverine Stack” — and the name alone explains why it’s spreading. Borrowed from the X-Men character’s fictional healing power, it refers to a real combination of two peptides, BPC-157 and TB-500, injected together on the promise of faster tissue repair. If you haven’t fielded a question about it yet, you likely will soon. Here’s what the evidence and the regulatory record actually say.
What you will learn in this article:
The Wolverine Stack pairs BPC-157 and TB-500, an informal name that has taken hold in sports medicine, regenerative medicine, and online peptide communities. The rationale behind it is mechanistic: BPC-157 is proposed to act primarily through angiogenesis and collagen synthesis pathways, while TB-500 is proposed to act through cellular migration and actin polymerization pathways. Stacking the two is based on the hypothesis that these complementary mechanisms could produce additive or synergistic effects on tissue repair. That’s a hypothesis, not a demonstrated outcome, and the distinction matters for anyone counseling a patient.
Part of the answer is simply that BPC-157 itself is already one of the most-asked-about peptides in aesthetic and regenerative practice. The gray market compounds the exposure: BPC-157 appears among the most-frequently-encountered problematic online peptide products, and online advertising for problematic peptides rose more than 300% between 2023 and 2024. Patients are very likely encountering the Wolverine Stack through unregulated sources and online communities rather than through a provider, which raises the stakes on getting ahead of the conversation.
Four points define the risk picture, and providers should hold all of them clearly in mind. There are no human clinical trials evaluating the BPC-157 plus TB-500 combination for any indication. Both compounds carry FDA safety risk designations and limited human safety data individually — BPC-157 is classified as a Category 2 bulk drug substance, reflecting FDA-identified risks including immunogenicity, peptide-related impurities, and limited human safety data — and their combined safety profile is essentially unknown. TB-500 is prohibited by the World Anti-Doping Agency (WADA). And both are compounded preparations without FDA approval; because BPC-157 is a Category 2 substance, the FDA may consider enforcement action against compounding it.
Put simply: combining two under-studied peptides doesn’t add up to evidence. It compounds the uncertainty.
When a patient raises the Wolverine Stack, the conversation should cover the evidence limitations, the regulatory concerns affecting both compounds, the WADA implications for any athlete, and the unknown safety profile of the combination itself. If a provider and patient jointly decide to proceed anyway, informed consent needs to do real work rather than serve as boilerplate, specifically addressing each of those same points. For a deeper look at the evidence base behind one half of this stack, our BPC-157 for providers review walks through what the human data does and doesn’t show.
Is the Wolverine Stack (BPC-157 + TB-500) safe?
There’s no basis to call it safe. No human clinical trials have evaluated the combination for any indication, and the combined safety profile is essentially unknown.
Is BPC-157 legal to prescribe?
BPC-157 is a Category 2 bulk drug substance, a designation reflecting FDA-identified safety risks. It is a compounded preparation without FDA approval, and the FDA may consider enforcement action for compounding Category 2 substances.
Is TB-500 banned for competing athletes?
Yes. TB-500 is prohibited by the World Anti-Doping Agency. Any patient who competes should understand this before considering the Wolverine Stack.
Does combining BPC-157 and TB-500 work better than either alone?
That’s the hypothesis behind the stack — that complementary mechanisms could produce additive or synergistic tissue repair — but it has not been tested. No human trials evaluate the combination for any indication.
What should informed consent cover if a patient wants to proceed with the Wolverine Stack?
Consent should specifically address the lack of human trials, the regulatory concerns for both compounds, the WADA implications for athletes, and the unknown safety profile of the combination.
Educate before a patient commits, not after. For the fuller evidence review behind BPC-157 specifically, see our BPC-157 for providers article, and for the broader peptide landscape, visit our peptide therapy for providers hub.
Free CME Training
Get instant access to a complete Botox® training module and earn 1 AMA PRA Category 1 CME at no cost. Covers facial anatomy, crow’s feet injection technique, patient consultation, and safety protocols.
Sign up for free access:
No credit card required. Learn more about this training →